As­traZeneca's Fasen­ra ex­pands ap­proval in chil­dren with se­vere asth­ma

As­traZeneca’s asth­ma treat­ment Fasen­ra will now be avail­able to younger pa­tients, height­en­ing the com­pe­ti­tion in a crowd­ed field of res­pi­ra­to­ry ri­vals.

The FDA has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER